Alkem Laboratories (539523) Stock Overview
A pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
539523 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alkem Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹4,937.05 |
| 52 Week High | ₹6,440.00 |
| 52 Week Low | ₹4,498.90 |
| Beta | 0.42 |
| 1 Month Change | -3.11% |
| 3 Month Change | 2.14% |
| 1 Year Change | -0.39% |
| 3 Year Change | 62.38% |
| 5 Year Change | 111.77% |
| Change since IPO | 257.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 539523 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.6% | 1.9% | 2.7% |
| 1Y | -0.4% | 13.1% | 1.2% |
Return vs Industry: 539523 underperformed the Indian Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: 539523 underperformed the Indian Market which returned 1.2% over the past year.
Price Volatility
| 539523 volatility | |
|---|---|
| 539523 Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 539523 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 539523's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 17,432 | Vikas Gupta | www.alkemlabs.com |
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms.
Alkem Laboratories Limited Fundamentals Summary
| 539523 fundamental statistics | |
|---|---|
| Market cap | ₹586.65b |
| Earnings (TTM) | ₹21.65b |
| Revenue (TTM) | ₹129.65b |
Is 539523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 539523 income statement (TTM) | |
|---|---|
| Revenue | ₹129.65b |
| Cost of Revenue | ₹47.64b |
| Gross Profit | ₹82.00b |
| Other Expenses | ₹60.35b |
| Earnings | ₹21.65b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 181.11 |
| Gross Margin | 63.25% |
| Net Profit Margin | 16.70% |
| Debt/Equity Ratio | 8.5% |
How did 539523 perform over the long term?
See historical performance and comparisonDividends
Does 539523 pay a reliable dividends?
See 539523 dividend history and benchmarks| Alkem Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Aug 08 2025 |
| Dividend Pay Date | Sep 24 2025 |
| Days until Ex dividend | 38 days |
| Days until Dividend pay date | 85 days |
Does 539523 pay a reliable dividends?
See 539523 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/30 14:48 |
| End of Day Share Price | 2025/06/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alkem Laboratories Limited is covered by 35 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| Shrikant Akolkar | Angel Broking Private Limited |